Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Item
http://www.wikidata.org/entity/Q41386664
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerationsUse of natalizumab in multiple sclerosis: current perspectives.Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS.New insights into the pharmacokinetics and pharmacodynamics of natalizumab treatment for patients with multiple sclerosis, obtained from clinical and in vitro studies.Disease activity return after natalizumab cessation in multiple sclerosis.Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies.The role of natalizumab in the treatment of multiple sclerosis: benefits and risks.Randomised natalizumab discontinuation study: taper protocol may prevent disease reactivation.Long-term evaluation of NEDA-3 status in relapsing-remitting multiple sclerosis patients after switching from natalizumab to fingolimod
P2860

Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads.

Item
http://www.wikidata.org/entity/Q41386664
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Natalizumab discontinuation in ...... its at therapeutic crossroads.
@en
type
label
Natalizumab discontinuation in ...... its at therapeutic crossroads.
@en
prefLabel
Natalizumab discontinuation in ...... its at therapeutic crossroads.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Natalizumab discontinuation in ...... fits at therapeutic crossroads
@en
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P698
P921